

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: U.S. Patent No. 6,884,434  
Title: TRANSDERMAL THERAPEUTIC SYSTEM WHICH CONTAINS A  
D2 AGONIST AND WHICH IS PROVIDED FOR TREATING  
PARKINSONISM, AND A METHOD FOR THE PRODUCTION  
THEREOF  
Issue Date: 26 April 2005  
Inventors: Walter Mueller and James V. Peck  
Assignees & Owners: LTS Lohmann Therapie-Systeme AG and Schwarz Pharma Limited

**SUBMITTED ELECTRONICALLY VIA EFS-WEB**

**30 November 2010**

Mail Stop Hatch-Waxman PTE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**ATTN: Mary Till, Esq.**

LETTER REGARDING USPTO DETERMINATION OF NEW PATENT EXPIRATION

DATE

This paper is in response to the “Notice of Final Determination” mailed 1 Nov 2010 (“Notice”). The Notice states that U.S. Patent No. 6,884,434 (“U.S. ‘434”) is eligible for a Patent Term Extension (“PTE”) of 743 days. The original expiration date of U.S. ‘434 is 18 March 2019. The Notice states that the new expiration date (including PTE term) is 26 April 2022. However, Applicant submits that the new expiration date is 30 March 2021, which is 743 days after the original expiration date, 18 March 2019. Applicant requests clarification.

Respectfully submitted,

HARNESS, DICKEY & PIERCE, P.L.C.

/ Leanne M. Rakers /

Leanne M. Rakers  
Attorney for Applicant  
Reg. No. 64,412  
Harness, Dickey & Pierce, P.L.C.  
7700 Bonhomme, Suite 400  
St. Louis, Missouri 63105  
314.726.7514 (direct)  
314.726.7501 (fax)